West Pharmaceutical Services Long-term debt, gross remained flat by 0.0% to $203.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $203.00M to $203.00M. Over 5 years (FY 2020 to FY 2025), Long-term debt, gross shows a downward trend with a -4.5% CAGR.
A decrease indicates deleveraging, which generally reduces financial risk, while an increase may signal expansion or acquisition financing.
This represents the total principal amount of long-term debt obligations carried on the balance sheet, excluding short-t...
Standard metric for all capital-intensive firms; essential for calculating debt-to-equity and net debt ratios.
other_debt_instrument_carrying_amount| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $254.60M | $254.60M | $253.50M | $252.90M | $252.40M | $209.80M | $209.20M | $208.60M | $208.10M | $207.50M | $207.00M | $206.40M | $205.90M | $203.00M | $203.00M | $203.00M | $203.00M | $203.00M | $203.00M | $203.00M |
| QoQ Change | — | +0.0% | -0.4% | -0.2% | -0.2% | -16.9% | -0.3% | -0.3% | -0.2% | -0.3% | -0.2% | -0.3% | -0.2% | -1.4% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | -0.9% | -17.6% | -17.5% | -17.5% | -17.6% | -1.1% | -1.1% | -1.1% | -1.1% | -2.2% | -1.9% | -1.6% | -1.4% | +0.0% | +0.0% | +0.0% |